Douglas J. Watson

Statistics

Publications

Citations

3.6K

H-Index

Active since

1973

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

McGill University

Auburn University

Centre Hospitalier de l’Université de Montréal

Douglas J. Watson is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacotherapy, medicine, and clinical pharmacology.

Publications per year

1973–2018

Publications

Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

Antonio M. Gotto, Edwin J. Whitney, Evan A. Stein et al. · Circulation · 2000 · 567 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database.

Douglas J. Watson, Thomas Rhodes, Harry A. Guess · PubMed · 2003 · 288 citations

Medicine, Health Sciences, Epidemiologic Methods +14

Lower Risk of Thromboembolic Cardiovascular Events With Naproxen Among Patients With Rheumatoid Arthritis

Douglas J. Watson, Thomas Rhodes, Bing Cai et al. · Archives of Internal Medicine · 2002 · 237 citations

Medicine, Internal Medicine, Pharmacotherapy +17

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

Richard H. Hunt, S. E. Harper, Douglas J. Watson et al. · The American Journal of Gastroenterology · 2003 · 163 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia††A list of study investigators appears in the Appendix.

John F. Paolini, Yale Mitchel, Robert Reyes et al. · The American Journal of Cardiology · 2007 · 161 citations

Pharmacy, Pharmacology, Pharmacotherapy +9

1–5 of 52